New Dosing Regimen for Birth Control Therapy
FDA has approved YAZ (3-mg drospirenone/20-mcg ethinyl estradiol), a new monophasic oral contraceptive and the first pill to combine 20 mcg of ethinyl estradiol with progestin drospirenone. According to Berlex Inc., a U.S. affiliate of Schering AG, the 24-day, active-pill regimen for YAZ results in less hormonal fluctuation than traditional oral contraceptives that provide 21 days of active pills. YAZ became available in the United States by prescription in April 2006.
“YAZ represents a clear advancement in oral contraception and underscores the Berlex commitment to provide novel and innovative [products for] birth control to allow for individual choice,” says Reinhard Franzen, president and CEO of Berlex Laboratories. “We are continuing our dialogue with FDA in order to take YAZ even further by bringing women the first oral contraceptive for the treatment of the emotional and physical symptoms of premenstrual dysphoric disorder.”